GTx shares dive after toremifene flunks PhIII cancer trial

GTx (NASDAQ:  GTXI) ‎reported yesterday afternoon that its prostate cancer prevention drug failed to perform significantly better than a placebo in a late-stage trial, and the news pushed its stock price into a 37 percent dive as one analyst announced that the data signalled "game over" for the cancer indication. Patients taking toremifene 20 mg had a 10.2 percent lower rate of prostate cancer than the control group, but that wasn't enough to achieve statistical significance....